Navigation Links
Soluble IL-4 Receptor - A new boon for asthmatics

Bronchial asthma, the disease which is never an easy combat for any practising physician, is now being avenged by a new drug. A soluble interleukin-4 receptor (IL-4R), which acts as an IL-4 antagonist, appears to be safe and effective in preventing a decline in lung function and in preventing asthma symptoms.

In their study, Dr. Larry C. Borish, from the University of Virginia Health Sciences Center in Charlottesville, and colleagues randomly selected 62 patients with symptoms pertaining to moderate persistent asthma. They were stopped from inhaling corticosteroids and were divided into two groups. In one group IL-4 receptor were given and to the other group placebo was given.

It was found that, after a 12-week trial, those in the IL-4R group,there was no decline in FEV1; however, lung function did decline among those receiving placebo.

This study is "the first...to demonstrate the potential clinical efficacy of a TH2 inhibitor for the treatment of asthma," the investigators note.

This soluble IL-4 receptor, which isn't a corticosteroid, selectivelyinhibits allergic mechanisms will be a new boon in the treatment strategy of asthma.

"These data demonstrate the critical role of IL-4 in the pathogenesis of asthma and the potential benefit of this approach to therapy," Dr. Borish and colleagues conclude.
'"/>




Page: 1

Related medicine news :

1. Soluble Ingredient Can Make Fatty Fast Foods Healthier
2. Toll-like Receptor (Tlr3) Attachment Leads To Lethal Encephalitis
3. Genetic Variation In Bitter-Taste Receptor Gene Increases Alcoholic Risk
4. Calcium Receptor Vital For Stem Cell Migration to Bone Marrow
5. Researchers Identify Lung Failure Therapy Receptor
6. Effects Of Certain Food Related To Single Pain Receptors
7. Receptor for H.pylori Identified in Stomach
8. Functional Differences In Estrogen Receptor Could Be A Therapeutic Target
9. Schizophrenia Complicates With Altered Receptor Activity
10. Definite Connection Between Receptor Levels and Cocaine Abuse Reveals PET Imaging
11. Aromatase Inhibitors Better Than Tamoxifen For Treating Receptor-Positive Early Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 13, 2017 , ... Apple Rehab Shelton Lakes , which specializes in ... the facility as part of a disaster drill on October 3rd. , Apple Rehab ... City Emergency Manager, as well as the Connecticut Long Term Care Mutual Aid ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... Leading ... their peers in Washington, D.C., for the 49th Congress of the International Society ... ., Vice President of the Center for Cancer and Blood Disorders at ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
Breaking Medicine Technology: